Fresh research: Patients rate Biofinity® multifocal higher for vision,
comfort, lens of choice
CooperVision has rounded out its Biofinity® line of silicone hydrogel lenses with a multifocal lens for presbyopic patients. And research shows that patients strongly prefer Biofinity® multifocal lenses over certain other multifocal lens brands for comfort and vision, right from the first fitting.
Worldwide, approximately one billion people have presbyopia—and that number is expected to double by 20501. In fact, an estimated 44% of eye care patients now suffer from presbyopia2. Many of those patients have found past experiences with multifocal contact lenses frustrating. For years, they’ve faced a dilemma when choosing multifocal lenses: all-day comfort vs. outstanding vision correction at all distances. The Biofinity® multifocal lens does away with the tradeoff, and research proves it. In clinical testing, Biofinity® multifocal lenses out-performed other brands on a range of measurements, including end-of-the-day comfort, vision quality, and intent to continue with a lens from the study.
The lens outperformed or was comparable to three popular competitor brands in the factors that CooperVision understands are important to you and your patients. Wearers more often reported superior vision correction and greater or comparable comfort compared to ACUVUE® OASYS® for PRESBYOPIA, Ciba Vision® AIR OPTIX® AQUA MULTIFOCAL, or PureVision® Multi-Focal3,4,5. Wearers also cited a higher likelihood of choosing our brand compared to ACUVUE® OASYS® for PRESBYOPIA and PureVision® Multi-Focal 3,5. Here’s a closer look at this revealing research.
Superior vision correction
Providing consistently clear vision for presbyopic patientscan be a challenge because multifocal lenses have to correct for three distances (near, intermediate, and far) in order to work successfully.
In the study between Biofinity® multifocal and ACUVUE® OASYS® for PRESBYOPIA, Biofinity® multifocal lenses were rated as superior for at-arms-length vision, near vision, distance vision, and overall vision quality, compared with ACUVUE® OASYS® for PRESBYOPIA by patients after two weeks of wear3. When compared to Ciba Vision® AIR OPTIX® AQUA MULTIFOCAL, Biofinity® multifocal lenses were rated superior for near vision and at-arms-length vision after one week of wear4. A third study also found that Biofinity® multifocal lenses were rated as superior to PureVision® Multi-Focal for near vision, at-arms-length vision, and overall vision quality after two weeks of wear5.
Biofinity® multifocal lenses use Balanced Progressive® Technology, a proven lens design that enables an individualised fit for each patient—and each eye. This approach has been shown to accurately and reliably correct vision at all three distances.
Superior comfort to PureVision® Multi-Focal.
As people get older, they’re not only prone to presbyopia—their eyes can become drier, too. And dryness can make lens wearing less comfortable.
Biofinity® multifocal lenses were rated significantly more comfortable upon insertion, during the day, and at the end of the day compared to PureVision® Multi-Focal after two weeks of wear5. In other studies, Biofinity® multifocal lenses were also rated comparably in comfort to ACUVUE® OASYS® for PRESBYOPIA and Ciba Vision® AIR OPTIX® AQUA MULTI-FOCAL upon insertion, during the day, and at the end of the day, after two weeks of wear 3,4. Biofinity® multifocal lenses feature Aquaform® Comfort Science™, which helps create a naturally wettable lens. The lenses are approved for extended wear (6 nights) in the U.S. and continuous wear (29 nights) in Europe and Canada. Aquaform® Comfort Science™ maximises the multifocal lens for both moisture and oxygen, enabling high wettability for the presbyopic eye and ensuring lenses are comfortable throughout the day.
Overall satisfaction higher than ACUVUE® OASYS® for PRESBYOPIA and PureVision® Multi-Focal.
In studies where lens wearers compared Biofinity® multifocal lenses to PureVision® Multi-Focal and ACUVUE® OASYS® for PRESBYOPIA, Biofinity lenses were rated higher in overall satisfaction after two weeks of wear3,5.
More patients say they’ll stay with Biofinity® over ACUVUE® OASYS® for PRESBYOPIA and PureVision® Multi-Focal.
In the study comparing Biofinity® multifocal to ACUVUE® OASYS® for PRESBYOPIA, 70% of patients at their final visit preferred Biofinity® multifocal3. Further, 78% of patients who said they intended to continue with a study lens chose Biofinity® multifocal lenses over ACUVUE® OASYS® for PRESBYOPIA3. In a separate study comparing Biofinity® multifocal to PureVision® Multi-Focal, 78% who said they intended to continue with a study lens also chose Biofinity® multifocal5.
About the studies
CooperVision commissioned studies to compare Biofinity® multifocal lenses against three key competitor products: ACUVUE® OASYS® for PRESBYOPIA, Ciba Vision® AIR OPTIX® AQUA MULTI-FOCAL, and PureVision® Multi-Focal. The studies were conducted in the U.S. Study evaluations were completed for each study lens at the initial visit, after one week of wear, and after two weeks of wear.
1 Holden BA, Fricke TR, Ho SM, et al. Global vision impairment due to uncorrected presbyopia. Arch Ophthalmol. 2008;126(12):1731-1739.
2 2010 SIS International Research Multifocal Study (Commissioned by CooperVision).
3 Clinical Evaluation of the Biofinity® Multifocal Compared to the Acuvue® Oasys™ for Presbyopia Lenses (2010); results on file.
4 Clinical Evaluation of the Biofinity® Multifocal Compared to the Ciba Air Optix® Aqua Multifocal Lenses (2010); results on file.
5 Clinical Evaluation of the Biofinity® Multifocal Compared to the PureVision® Multi-Focal Lenses (2010); results on file
ACUVUE® and OASYS® are registered trademarks of Johnson & Johnson Vision Care, Inc.
AIR OPTIX® and AQUA MULTIFOCAL are registered trademarks of CIBA VISION® Corporation.
PureVision® is a registered trademark of Bausch & Lomb, Inc.